Yifei Cai

Associate Research Scientist in Molecular and Cellular Neuroscience

Deciphering molecular mechanisms of axonal pathology in Alzheimer’s’ disease


As a postdoctoral researcher, I am currently focused on uncovering the subcellular proteomes of neurons and glial cells and characterizing the molecular and cellular functions of these compartments in Alzheimer’s disease. To achieve this, I have developed a multidisciplinary toolset comprising molecular and cellular biology, imaging, and bioinformatics approaches, including proximity labeling proteomics, iPSC-induced human neurons and glia for disease modeling, high-resolution confocal imaging, longitudinal in vivo two-photon imaging, super-resolution pan-expansion microscopy, electron microscopy, spatial transcriptomics, RNA in situ hybridization, and bioinformatics analysis. I have applied these tools to investigate Alzheimer’s disease models, including human AD postmortem brains, human iPSC-derived neuron-glia co-culture AD model, and AD-model mice.
My recent work has focused on understanding the formation of plaque-associated axonal spheroids (PAAS) in Alzheimer’s disease. PAAS disrupt axonal electrical conduction and neuronal network function and correlate with AD severity, but their formation mechanisms are not well understood. I have used proximity labeling proteomics of axonal spheroids in human AD postmortem brains and mice to uncover the molecular architecture of PAAS. I also developed a human iPSC-derived AD model that recapitulates PAAS pathology for mechanistic studies. Through these approaches, I identified hundreds of previously unknown PAAS-enriched proteins and signaling pathways, including PI3K/AKT/mTOR. I found that phosphorylated mTOR was highly enriched in PAAS and strongly correlated with disease severity in humans. Importantly, pharmacological mTOR inhibition in iPSC-derived human neurons or AAV-mediated knockdown in mice led to a marked reduction of PAAS pathology. These findings provide a novel platform to examine mechanisms of axonal pathology in neurodegeneration and to evaluate the therapeutic potential of novel targets. I am currently preparing a co-corresponding first-author article for publication in a peer-reviewed journal (in revision, also available on bioRxiv).
Additionally, I have contributed to a related project that demonstrated the functional impact of axonal spheroids in disrupting axonal electrical conduction and impairing neuronal circuitries. In this project, I elucidated the super-resolution subcellular structures within axonal spheroids, which allowed me to co-author a research article in Nature (2022).
[Picture]
Plaque-associated axonal spheroids in Alzheimer's disease human brain
[Picture]
Antibody-based proximity labeling of axonal spheroids in Alzheimer's human brains
[Picture]
Proximity labeling subcellular proteomics of axonal spheroid in Alzheimer's human brains
[Picture]
iPSC modeling of plaque-associated axonal spheroids in human neuron-glia co-culture
[Picture]
Reversibility of axonal spheroids in iPSC-derived human neurons by pharmacological inhibition of mTOR signaling
[Picture]
Reduction of axonal spheroid pathology by mTOR heterozygous knockout in AD model mice

Publications


PLD3 affects axonal spheroids and network defects in Alzheimer’s disease


Peng Yuan, Mengyang Zhang, Lei Tong, Thomas M Morse, Robert A McDougal, Hui Ding, Diane Chan, Yifei Cai, Jaime Grutzendler

Nature, 2022, pp. 1-10


Spatial proteomics and iPSC modeling uncover mechanisms of axonal pathology in Alzheimer's disease


Yifei Cai, Jean Kanyo, Raushan Wilson, Mohammad Shahid Mansuri, Pablo Leal Cardozo, Derek Goshay, Zichen Tian, Amber Braker, Hoang Kim Trinh, TuKiet Lam, Kristen Brennand, Angus C. Nairn, Jaime Grutzendler

bioRxiv, 2022